Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

Pembrolizumab plus lenvatinib is an effective and tolerable treatment for mRCC also in the real-world setting.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2025-05-09
DOI
https://doi.org/10.1007/s00262-025-04019-x
Citations
3
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
4.56
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

Maria Teresa Bourlon, Tarek Taha, Bohuslav Melichar, Zin Myint et al.
3 citations
Cancer Immunology Immunotherapy
Renal cell carcinoma treatment
4.56
article

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

Maria Teresa Bourlon, Tarek Taha, Bohuslav Melichar, Zin Myint, Sebastiano Buti, Camillo Porta, Matteo Santoni, Thomas Büttner, Jakub Kucharz, Andrey Soares, Veronica Mollica, Ravindran Kanesvaran, Enrique Grande, Javier Molina‐Cerrillo, Mimma Rizzo, Aristotelis Bamias, Se Hoon Park, Ray Manneh Kopp, Francesco Massari, Yüksel Ürün, Fernando Sabino Marques Monteiro, Ugo De Giorgi, Teresa Alonso‐Gordoa, Renate Pichler, Alessandro Rizzo, Umberto Basso, Jawaher Ansari, Tomáš Büchler, Hana Študentová, Giuseppe Fornarini, Pasquale Rescigno
article en
3 citations

Abstract

Pembrolizumab plus lenvatinib is an effective and tolerable treatment for mRCC also in the real-world setting.

Cancer Immunology ImmunotherapyVol. 74(7)
University of Parma (IT), Royal Marsden NHS Foundation Trust (GB), University of Kentucky (US), Innsbruck Medical University (AT), Ankara University (TR), Universität Innsbruck (AT), National and Kapodistrian University of Athens (GR), Charles University (CZ), University Hospital Bonn (DE), Hospital Israelita Albert Einstein (BR), Samsung Medical Center (KR), Markey Cancer Center (US), Popular University of Cesar (CO), Tawam Hospital (AE), Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), University Hospital in Motol (CZ), Istituto Oncologico Veneto (IT), Azienda USL di Bologna (IT), Istituto Tumori Bari (IT), National Cancer Centre Singapore (SG), Ospedale Policlinico San Martino (IT), Hospital Sírio-Libanês (BR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Istituti di Ricovero e Cura a Carattere Scientifico (IT), MD Anderson Cancer Center Madrid (ES), Hospital Universitario Ramón y Cajal (ES), Ospedale di Macerata, University of Macerata (IT), Palacký University Olomouc (CZ), Newcastle University (GB), University of Bologna (IT)
Openalex Percentile: Top 6%
Renal cell carcinoma treatment
4.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.